Sanofi Pasteur has entered into a four-year strategic partnership with the US Naval Medical Research Center (NMRC) to develop a diarrhoea vaccine.

The core enterotoxigenic escherichia coli (ETEC) adhesin vaccine technology developed by NMRC had been licensed to Sanofi with another technology that packages the adhesin with a toxoid vaccine component co-developed by NMRC and the University of Colorado in Denver.

Sanofi Pasteur president and CEO Wayne Pisano said that the company would expedite the development of this vaccine for eventual licence and sale worldwide.

“This multiyear project will provide a solid basis for launching clinical development,” he said

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that this vaccine has the potential to curtail the number and severity of food-borne illnesses due to ETEC, and it may also decrease the risk of post-infectious irritable bowel syndrome, which afflicts one in ten who experience travellers’ diarrhoea.”

See Also:

Following the successful four-year pre-clinical research, full-scale clinical development of a multivalent adhesin-based ETEC vaccine will be initiated.